ALPHAMAB ONCOLOGY
康寧傑瑞生物製藥
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT

A PHASE I/II CLINICAL TRIAL OF JSKN033 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED OR METASTATIC SOLID TUMORS WAS APPROVED IN AUSTRALIA

This announcement is made by Alphamab Oncology (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the "**Board**") of directors ("**Directors**") of the Company is pleased to announce that a phase I/II clinical trial ("**JSKN033-101**") of JSKN033 independently developed by our Group for the treatment of human epidermal growth factor receptor 2 ("**HER2**")-expressing advanced or metastatic solid tumors, has been approved by the Bellberry Human Research Ethics Committee in Australia.

JSKN033-101 is an open-label, multicenter, phase I/II clinical trial which consists of two phases: (i) the phase I (the dose escalation phase) designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JKSN033 in patients with HER2-expressing advanced or metastatic solid tumors and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (the "**RP2D**"); and (ii) the phase II (the dose expansion phase) designed to evaluate the efficacy and safety of JSKN033 in HER2-expressing gastrointestinal tumors at the RP2D.

ABOUT JSKN033

JSKN033 is a global first subcutaneous formulation with JSKN003, the HER2 bispecific antibody-conjugated drug and Envafolimab, the programmed death ligand 1 ("**PD-L1**") monoclonal antibody, developed by our Group. JSKN003 is a biparatopic HER2-targeting antibody-drug conjugate, of which a topoisomerase I inhibitor is linked to the N glycosylation site of the antibody KN026 (a recombinant humanized anti-HER2 bispecific antibody) via the glycosite-specific conjugation. Envafolimab is a Fc fusion protein consisting of humanized anti-PD-L1 single domain antibody and human IgG1 Fc fragment, which has been approved by the National Medical Products Administration of China (國家藥品監督管理局) (the "**NMPA**") as the global-first subcutaneous injection PD-L1 inhibitor in November 2021.

ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house clinical pipeline of the Company includes the oncology drug candidates with one approved for marketing by the NMPA, three in late clinical stage and two in phase I clinical trial stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological new drug candidates that could potentially benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market JSKN033, JSKN003 and KN026 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, December 8, 2023

As of the date of this announcement, the Board comprises Dr. XU Ting as the chairman and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.